Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Daniel Nava Rodrigues et al.|The Lancet Oncology|2019Cited by 643
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Johann S. de Bono, Beshara Sheehan et al.|European Urology|2019Cited by 464
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Johann S. de Bono, Joaquı́n Mateo et al.|Cancer Discovery|2017Cited by 422
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquı́n Mateo, Johann S. de Bono, George Seed et al.|Journal of Clinical Investigation|2019Cited by 303
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancerDaniel Nava Rodrigues, Charles G. Drake, Pasquale Rescigno et al.|Journal of Clinical Investigation|2018Cited by 209